Lara Jean Ancona
Partner/Director
516-393-2245
Artificial Intelligence (AI)
- Overview
- Attorneys
- Insights
The health care sector is rapidly evolving with the integration of artificial intelligence (AI), promising improvements in patient care, operational efficiency, revenue cycle, and medical research. However, this innovation also brings unique legal challenges and regulatory concerns, particularly in clinical settings. Garfunkel Wild’s AI Practice Group is at the forefront of legal innovation in the health care sector, and the unique challenges faced by health care providers as they navigate the complex and rapidly evolving intersection of AI technology and health care. Garfunkel Wild’s AI Practice Group includes attorneys from various disciplines across the firm, including experts from its Technology and Cybersecurity, Employment and Workforce Management, Managed Care, Litigation and Alternative Dispute Resolution, and Investigations, Audits and Regulatory Compliance practice groups. The AI Practice Group combines a wide breadth of health care, compliance and technological expertise with practical and strategic guidance, and offers a wide spectrum of legal services to clients in the health care sector, including advising clients on emerging issues in regulatory compliance, reviewing and negotiating AI software agreements, data privacy and security, intellectual property, clinical applications, risk management, litigation and dispute resolution, patient outcomes and the clinical application of AI based technology. At Garfunkel Wild, we recognize that the use of AI in a health care setting extends beyond merely adopting new technology. It involves a commitment to enhancing patient outcomes while simultaneously ensuring compliance with complex rules and regulations.
We proudly serve a diverse range of clients, including hospitals, physician groups, health care systems, biotech companies, and clinical research institutions. Our deep understanding of both the health care and technology sectors allows us to provide targeted, strategic advice that drives innovation, promotes meaningful impact on patient care while safeguarding our clients’ interests.
Team
FDA Seeks Comment on AI-Enabled Medical Devices
The U.S. Food and Drug Administration (FDA) has issued a Request for Public Comment to gather feedback on practical approaches for measuring and evaluating the performance of AI-enabled medical devices in real-world clinical settings to help the FDA ensure such medical devices remain safe and effective throughout their life cycle. This move underscores the FDA’s increasing focus on post-market oversight of AI technologies, including generative AI, and their evolving behavior in dynamic healthcare environments.
The health care sector is rapidly evolving with the integration of artificial intelligence (AI), promising improvements in patient care, operational efficiency, revenue cycle, and medical research. However, this innovation also brings unique legal challenges and regulatory concerns, particularly in clinical settings. Garfunkel Wild’s AI Practice Group is at the forefront of legal innovation in the health care sector, and the unique challenges faced by health care providers as they navigate the complex and rapidly evolving intersection of AI technology and health care. Garfunkel Wild’s AI Practice Group includes attorneys from various disciplines across the firm, including experts from its Technology and Cybersecurity, Employment and Workforce Management, Managed Care, Litigation and Alternative Dispute Resolution, and Investigations, Audits and Regulatory Compliance practice groups. The AI Practice Group combines a wide breadth of health care, compliance and technological expertise with practical and strategic guidance, and offers a wide spectrum of legal services to clients in the health care sector, including advising clients on emerging issues in regulatory compliance, reviewing and negotiating AI software agreements, data privacy and security, intellectual property, clinical applications, risk management, litigation and dispute resolution, patient outcomes and the clinical application of AI based technology. At Garfunkel Wild, we recognize that the use of AI in a health care setting extends beyond merely adopting new technology. It involves a commitment to enhancing patient outcomes while simultaneously ensuring compliance with complex rules and regulations.
We proudly serve a diverse range of clients, including hospitals, physician groups, health care systems, biotech companies, and clinical research institutions. Our deep understanding of both the health care and technology sectors allows us to provide targeted, strategic advice that drives innovation, promotes meaningful impact on patient care while safeguarding our clients’ interests.
Team
FDA Seeks Comment on AI-Enabled Medical Devices
The U.S. Food and Drug Administration (FDA) has issued a Request for Public Comment to gather feedback on practical approaches for measuring and evaluating the performance of AI-enabled medical devices in real-world clinical settings to help the FDA ensure such medical devices remain safe and effective throughout their life cycle. This move underscores the FDA’s increasing focus on post-market oversight of AI technologies, including generative AI, and their evolving behavior in dynamic healthcare environments.
